Royalty Pharma plc

Informe acción NasdaqGS:RPRX

Capitalización de mercado: US$16.3b

Royalty Pharma Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Royalty Pharma de 12.8% y 6.8% por año respectivamente. Se prevé que el BPA crezca en un 13% al año. Se espera que la rentabilidad financiera sea de 23.1% en 3 años.

Información clave

12.8%

Tasa de crecimiento de los beneficios

13.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals23.7%
Tasa de crecimiento de los ingresos6.8%
Rentabilidad financiera futura23.1%
Cobertura de analistas

Good

Última actualización28 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 12
Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Recent updates

Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21

Oct 14
Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21

Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)

Oct 09
Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)

Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt

Aug 28
Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating

Aug 22

Royalty Pharma: Busy Putting Capital To Work

Aug 11

Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21

Jul 22
Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21

Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 12
Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Royalty Pharma: Solid Start Of The Year, Buy Confirmed

May 11

Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Apr 28
Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21

Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Apr 25
Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares

Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Apr 04
Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?

Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Feb 22
Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem

Royalty Pharma: Solid Operational Performance

Feb 19

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Jan 31
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21

Royalty Pharma: One Of The Best Names In Pharmaceuticals

Jan 22

Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Dec 26
Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

May 12
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Apr 20
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20

Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Jan 16
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20

Royalty Pharma to co-fund development of schizophrenia drug with Merck

Oct 12

Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth

Aug 18

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:RPRX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/20263,0711,2613,0073,5907
12/31/20252,8361,1192,7013,2907
12/31/20242,6778052,5873,1597
6/30/20242,2386734012,669N/A
3/31/20242,2397991,0192,619N/A
12/31/20232,3551,1358722,988N/A
9/30/20232,3241841,4222,785N/A
6/30/20232,3612555222,750N/A
3/31/20232,3593323742,718N/A
12/31/20222,237434022,144N/A
9/30/20222,2475074012,064N/A
6/30/20222,2594663121,995N/A
3/31/20222,2786022631,952N/A
12/31/20212,289620-1742,018N/A
9/30/20212,286783-7322,093N/A
6/30/20212,239972-1592,132N/A
3/31/20212,195493-4962,090N/A
12/31/20202,122495-1482,035N/A
9/30/20202,0081,7451041,947N/A
6/30/20201,9341,8637931,858N/A
3/31/20201,8802,0521,0931,705N/A
12/31/20191,8142,349-541,667N/A
12/31/20181,7951,3781,3491,618N/A
12/31/20171,5981,210N/A1,418N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (12.8% al año) de RPRX es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que los beneficios (12.8% al año) de RPRX crezcan menos que el mercado US (15.4% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de RPRX crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (6.8% al año) de RPRX crezcan más despacio que el mercado de US (8.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 6.8% al año) de RPRX crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de RPRX sea alta dentro de 3 años (23.1%)

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y